Chemotherapy With CMF for Triple-Negative Breast Cancer With Carcinoma Erysipelatoides

JAMA Dermatology - United States
doi 10.1001/jamadermatol.2016.2502
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Medical Association (AMA)

Related search

Comparative Analysis of Different Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer

Tumors of female reproductive system
2017English

Prognostic Factors for Triple-Negative Breast Cancer Patients Receiving Preoperative Systemic Chemotherapy

Clinical Breast Cancer
Cancer ResearchOncology
2013English

Triple-Negative Breast Cancer

2018English

CD44v9 as a Poor Prognostic Factor of Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy

Breast Cancer
Nuclear MedicineRadiologyPharmacologyOncologyImagingMedicine
2018English

Dasatinib Sensitises Triple Negative Breast Cancer Cells to Chemotherapy by Targeting Breast Cancer Stem Cells

British Journal of Cancer
Cancer ResearchOncology
2018English

The Main Parameters of Cellular Immunity in Patients With Triple-Negative Breast Cancer: Relationship With Efficiency of Chemotherapy

Medical Immunology (Russia)
AllergyImmunology
2018English

Triple-Negative Breast Cancer: Clinicopathological Characteristics and Relationship With Basal-Like Breast Cancer

Modern Pathology
Forensic MedicinePathology
2009English

CAF vs. CMF Combination Chemotherapy in Advanced Breast Cancer Patients

International Journal of Science and Research (IJSR)
2016English

Neutrophil–lymphocyte Ratio Predicts Response to Chemotherapy in Triple-Negative Breast Cancer

Current Oncology
Oncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy